Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration

Hepatology

Volumn 12, Issue 2, 1990, Pages 322-334

  Nakagawa, Michiko ^a   Colombo, Carla ^b   Setchell, Kenneth D R ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; URSODEOXYCHOLIC ACID; DEOXYCHOLIC ACID; DRUG DERIVATIVE;

ADOLESCENT; ARTICLE; BILE COMPOSITION; CLINICAL ARTICLE; CYSTIC FIBROSIS; FEMALE; HUMAN; LIVER DISEASE; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHOOL CHILD; CHILD; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLISM;

ADOLESCENT; BILE ACIDS AND SALTS; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTIC FIBROSIS; DEOXYCHOLIC ACID; FEMALE; HUMAN; LIVER DISEASES; MALE; MASS FRAGMENTOGRAPHY; SPECTRUM ANALYSIS, MASS; URSODEOXYCHOLIC ACID;

EID: 0025193141     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.1840120221     Document Type: Article

References (55)

1. State of the art of cystic fibrosis
2. Cystic fibrosis: a challenging long‐term chronic disease
3. Hepatobiliary disease in cystic fibrosis: a survey of current issues and concepts
4. Gastrointestinal manifestations of cystic fibrosis: a review
5. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis: a review
6. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?
7. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow‐up: a pilot study
8. The effect of ursodeoxycholic acid in primary sclerosing cholangitis: a comparison to primary biliary cirrhosis [Abstract]
9. Effect of different doses of ursodeoxycholic acid in chronic liver diseases
10. Excessive fecal taurine loss predisposes to taurine deficiency in cystic fibrosis
11. Effect of taurine supplements on fat absorption in cystic fibrosis
12. Effect of taurine supplementation on fat and bile acid absorption in patients with cystic fibrosis
13. Enterohepatic circulation in man: a simple method for the determination of duodenal bile acids
14. A rapid method for the quantitative extraction of bile acids and their conjugates from serum using commercially available reverse phase octadecylsilane bonded silica cartridges
15. Mass spectrometry of bile acids
16. Inborn errors of bile acid synthesis
17. Chromatographic methods for bile acid analysis
18. High pressure liquid chromatographic analysis of conjugated bile acids in human bile: simultaneous resolution of sulphated and unsulfated lithocholyl amidates and the common conjugated bile acids
19. A modified gas‐liquid chromatographic procedure for the rapid determination of bile acids in biological fluids
20. Analysis of metabolic profiles of bile acids in urine using a lipophilic anion exchanger and computerized gas‐liquid chromatography/mass spectrometry
21. Analysis of 3‐sulfated and non‐sulfated bile acids by one‐step hydrolysis and high performance liquid chromatography
22. Serum bile acid analysis: the application of liquid‐gel chromatographic techniques and capillary column gas chromatography and mass spectrometry
23. Liquid‐solid extraction, liquid‐gel chromatography and capillary column gas chromatography in the analysis of bile acids from biological samples
24. Mass spectrometry of bile acids
25. Liver disease and common bile duct stenosis in cystic fibrosis
26. Intestinal bile salts in cystic fibrosis
27. Aspects of bile acid metabolism in cystic fibrosis
28. Malabsorption of bile acids in children with cystic fibrosis
29. Bile acid malabsorption in cystic fibrosis with and without pancreatic insufficiency
30. Ursodeoxycholic acid for chronic liver disease
31. Ursodeoxycholic acid (UDCA) treatment of primary biliary cirrhosis: clinical and histological results of a controlled study
32. Ursodeoxycholic acid for primary biliary cirrhosis
33. Effects of ursodeoxycholic acid in primary biliary cirrhosis and primary sclerosing cholangitis
34. Hypercholeresis induced by ursodeoxycholic acid and 7‐ketolithocholic acid in the rat: possible role of biocarbonate transport
35. Bile acid hepatotoxicity and the rationale of UDCA therapy in chronic cholestatic liver disease: some hypotheses
36. Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids
37. Fecal bile acids
38. Techniques for extraction and isolation of bile acids
39. Hepatic bile acid metabolism during early development revealed from the analysis of human fetal gall‐bladder bile
40. Similarity of unusual bile acids in human umbilical cord blood and amniotic fluid from newborns and sera and urine from adult patients with cholestatic liver diseases
41. Changes in biliary lipid and biliary bile acid composition in patients after administration of ursodeoxycholic acid
42. Quantification of individual serum bile acids in patients with liver diseases using high‐performance liquid chromatography
43. Dietary glycine and taurine on bile acid conjugation in man
44. Hepatic taurine concentration and dietary taurine as regulators of bile acid conjugation with taurine
45. The effect of tauroursodeoxycholic acid and taurine supplementation on biliary bile acid composition
46. Bile acid–induced liver toxicity: relation to the hydrophobichydrophilic balance of bile acids
47. Protective effect of ursodeoxycholic acid against cholestatic and hepatotoxic effects of lithocholic acid
48. Tauroursodeoxycholate prevents taurocholate induced cholestasis